Table 4.
Female Participants (n = 6) | Male Participants (n = 6) | Treatment Effects | Gender Effects | Treatment × Gender Interaction | |||
---|---|---|---|---|---|---|---|
Baseline | 120 min | Baseline | 120 min | P values | |||
FGF21(pg/mL) | 122.0 ± 55.2 | 63.2 ± 24.7 | 54.9 ± 8.7 | 40.1 ± 8.4 | 0.04 | 0.29 | 0.20 |
Leptin (pg/mL) | 7937 ± 2998 | 4926 ± 2176 | 3173 ± 1122 | 2172 ± 803 | 0.001 | 0.20 | 0.05 |
Adiponectin (ng/ mL) | 8770 ± 1329 | 7299 ± 1231 | 7871 ± 378 | 7329 ± 509 | <0.001 | 0.75 | 0.03 |
TNFα (pg/mL) | 2.7 ± 0.4 | 2.6 ± 0.3 | 3.3 ± 0.2 | 3.4 ± 0.3 | 0.92 | 0.16 | 0.30 |
N = 12; Values are mean ± SEM; The treatment effects, gender effects and interactions between treatment and gender were tested using linear mixed effects model while controlling for the baseline measurements.
Abbreviations: BAT, brown adipose tissue; FGF21, fibroblast growth factor-21; TNFα, tumor necrosis factor-α.